In a landmark step for neural technology, researchers have confirmed the safety of graphene-based brain implants in the first human trial of its kind. The study, conducted by InBrain Neuroelectronics, marks a critical milestone in the development of high-resolution brain-computer interfaces (BCIs) designed to treat neurological disorders like Parkinson’s disease and epilepsy.
The First Human Trial: Safety Confirmed
The trial, which took place in Spain, involved the temporary placement of a graphene-based implant on the cerebral cortex of a patient. The device, developed by InBrain Neuroelectronics—a spin-off from the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and ICREA—was designed to record and decode neural signals with unparalleled resolution. According to the company, the procedure was completed without complications, and the implant demonstrated no adverse effects during its brief placement.
“Our goal is to have a commercial product capable of decoding and mapping brain signals to address a range of neurological disorders,” said Carolina Aguilar, CEO and co-founder of InBrain Neuroelectronics. The company’s platform, which combines flexible graphene hardware with AI-driven data analytics, aims to personalize therapies for conditions that currently lack effective treatments.
Why Graphene?
Graphene, a single layer of carbon atoms arranged in a two-dimensional lattice, has long been hailed as a “wonder material” for its strength, flexibility, and conductivity. Discovered in 2004 by researchers at the University of Manchester—who later won the Nobel Prize in Physics for their work—graphene is now being explored for applications ranging from batteries to medical devices. Its use in brain implants offers several advantages over traditional materials, including higher resolution, reduced invasiveness, and the ability to conform to the brain’s delicate surface.
The InBrain implant, described as “skin-like” and ultra-thin, can record neural activity from up to 1,024 contact points, a significant leap from existing technologies. This level of precision could enable more targeted therapies for patients with movement disorders, epilepsy, or even paralysis, where real-time monitoring and modulation of brain activity are critical.
“Graphene enables a new class of flexible, high-resolution neurotechnology that could revolutionize how we treat neurological disorders.”
— InBrain Neuroelectronics
A Step Toward Personalized Neurological Care
Neurological disorders, including Parkinson’s disease, epilepsy, and Alzheimer’s, affect hundreds of millions of people worldwide and represent the second-leading cause of death globally, according to the World Health Organization. Current treatments often rely on invasive procedures or medications with limited efficacy, leaving many patients with few options. The development of graphene-based BCIs could fill this gap by offering therapies tailored to individual brain activity patterns.
InBrain’s platform has already received the U.S. Food and Drug Administration’s Breakthrough Device Designation for Parkinson’s disease, a status reserved for technologies that reveal potential to address unmet medical needs. The company’s work aligns with broader efforts in the field, including those by Neuralink and other biotech firms, to restore lost sensory or motor functions through brain-machine interfaces.
What’s Next?
While the recent trial focused on safety, InBrain Neuroelectronics plans to expand its research to evaluate the implant’s long-term efficacy in treating specific conditions. The company’s technology is part of a larger initiative funded by the European Union’s NextGenerationEU recovery plan, which supports innovation in microelectronics and semiconductors. If successful, these advancements could pave the way for a new era of personalized neurological care, offering hope to patients with debilitating disorders.
For now, the confirmation of safety in human trials is a promising sign that graphene-based implants may soon move from the lab to clinical use, bringing the field one step closer to transforming how we understand and treat the brain.
